MA-LOADSPRING-SOLUTIONS
14.9.2022 19:31:33 CEST | Business Wire | Press release
LoadSpring Solutions, Inc., the enterprise market leader in project platform solutions, has accepted a strategic majority interest investment from Blattner Technologies. Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
LoadSpring’s partnership with Blattner Technologies aligns with our industry focus on digital transformation and advancing data usability, analytics, machine learning, and artificial intelligence. Blattner’s focus on AI and predictive technologies will help lead to our customers' next generation of advancement.
“Today’s investment announcement will enable LoadSpring to rapidly expand its vision of driving the project controls industry to a future where it aspires to be. This new partnership, including the additional board membership, will accelerate our platform development and AI/analytics technology innovation to enable faster geographic and industry expansion, truly unlocking LoadSpring’s potential. Together, our expertise in providing global cloud solutions for project-based organizations and our new partner's expertise in building companies will provide next-generation solutions for our customers,” states Eric Leighton, President and CEO of LoadSpring Solutions, Inc.
Blattner Technologies’ CEO Russ Blattner says, “LoadSpring has the resources and tools to complement the list of companies Blattner Technologies is acquiring in our mission to build a predictive transformation model that takes our customers from the basics of data management and analytics to operationalizing AI/ML and true predictive analytics throughout an organization.”
LoadSpring’s global office locations and executive management teams will remain in place, with Eric Leighton continuing in his leadership role as President and CEO. Blattner Technologies representatives Russ Blattner and John Leschorn, along with Terrance Berland, co-founder of Unicorn & Lion, LLC, will join the LoadSpring Board of Directors, providing operational and technology vision to drive customer solutions into the future.
“This investment combines secure technology infrastructure and next-generation tools and analytics to create a truly distinctive solution offering for customers. This is an industry trend that will continue as organizations better understand the power of controlling and mining their data and look for partners that can bring them complete solutions, not just pieces,” says Terrance Berland, a member of the Forbes Technology Council.
About Blattner Technologies
Nashville, TN Blattner Technologies – Building on a 115-year legacy of innovation by the Blattner family of companies, Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
About LoadSpring
Founded in 1999, LoadSpring is a global project management provider obsessed with offering advanced managed cloud services. LoadSpring delivers expert project management and control solutions, fast data and business intelligence access, and hundreds of best-of-breed project-based applications. Data safety is assured through SOC 2 Type II security certification, providing an impenetrable cloud environment. LoadSpring customers and partners get higher productivity and ROI through our proprietary project platform while reducing the burden on their IT departments.
For more information, contact Stacey Witt at switt@loadspring.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006196/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom